RTS Swissmedic Fees Rise 35% on July 1, 2026

Switzerland’s drug regulator Swissmedic is raising its hourly billing rate by 35% to CHF 270 from CHF 200, effective July 1, 2026. The revised Ordinance on Fees also introduces a new registration fee for medical devices. Companies must pay the new rates for services provided after June 30, 2026, while ongoing procedures use the service date to determine which rate applies.

Swissmedic’s New Fee Structure Takes Effect

The revised Ordinance on the Fees charged by the Swiss Agency for Therapeutic Products enters into force on July 1, 2026. The hourly rate for work charged on an hourly basis increases to CHF 270 from the existing CHF 200. Services provided up to June 30, 2026 continue to use the old hourly rate of CHF 200. For ongoing procedures, the date the service is provided determines which rate applies.

Medical Device Registration Fees Introduced

The revision introduces a registration fee for medical devices, a new cost for manufacturers. This change expands Swissmedic’s fee model beyond pharmaceutical products. The exact amount of the device registration fee was not disclosed in the announcement. Companies must budget for both the increased hourly rates and the new device fees when planning regulatory submissions.

Impact on Pharmaceutical and Medtech Companies

The 35% increase in hourly rates will raise costs for drug approvals, clinical trial reviews, and post-market surveillance. Medtech firms face additional expenses from the new device registration requirement. Swiss healthcare providers and patients may see higher drug and device prices as companies pass through regulatory costs.

Final Thoughts

Swissmedic’s 35% fee hike and new device registration charges will increase regulatory costs for pharma and medtech firms starting July 1. Companies should expect higher approval timelines and budgets for Swiss market entry.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.